Zurcher Kantonalbank Zurich Cantonalbank Lowers Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Zurcher Kantonalbank Zurich Cantonalbank cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 32.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 60,900 shares of the company’s stock after selling 29,118 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned 0.06% of Neurocrine Biosciences worth $7,017,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in NBIX. Ashton Thomas Private Wealth LLC acquired a new position in Neurocrine Biosciences in the second quarter valued at $28,000. Innealta Capital LLC purchased a new stake in Neurocrine Biosciences in the 2nd quarter valued at about $30,000. EdgeRock Capital LLC acquired a new position in shares of Neurocrine Biosciences during the 2nd quarter valued at about $35,000. Blue Trust Inc. lifted its holdings in shares of Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after acquiring an additional 220 shares during the period. Finally, Plato Investment Management Ltd boosted its position in shares of Neurocrine Biosciences by 44.1% in the second quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock worth $59,000 after acquiring an additional 130 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on NBIX shares. Barclays dropped their price target on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. JPMorgan Chase & Co. increased their target price on Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Jefferies Financial Group raised their price objective on Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a report on Monday, August 19th. Finally, Royal Bank of Canada decreased their target price on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a report on Friday, October 4th. Five analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX opened at $126.75 on Monday. The stock has a market cap of $12.83 billion, a price-to-earnings ratio of 33.98 and a beta of 0.35. Neurocrine Biosciences, Inc. has a one year low of $110.95 and a one year high of $157.98. The business’s 50-day simple moving average is $119.26 and its 200 day simple moving average is $131.48.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.